AGP Executive Report
Last update: 7 hours agoUS–Liechtenstein Pharma Trade: The US Commerce Department has put Liechtenstein (along with 19 other jurisdictions) on a zero-tariff list for specific speciality medicines and related ingredients, even as a broader 100% tariff on certain patented pharma imports ramps up from Sept. 29. The exemption is product-specific (rare diseases, fertility drugs, cell and gene therapies, antibody-drug conjugates, nuclear and plasma-derived therapies, plus some veterinary products) and hinges on qualifying under an eligible trade/security framework. Healthcare Workforce Policy: Ireland is temporarily relaxing a “50:50 rule” limiting non-EEA workers to half of an organisation’s staff to ease healthcare shortages—an issue that has hit nursing homes, home-care and disability services hardest. EU Biotech Access: Neuraxpharm’s NEZGLYAL® (leriglitazone) has received EU marketing authorisation under exceptional circumstances for childhood cerebral adrenoleukodystrophy, with Germany expected to be the first launch market. Cross-border Industry Links: The Việt Nam–EFTA free trade deal is expected to open new export opportunities for seafood, but firms will need to meet stricter quality, traceability and sustainability requirements.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report ]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/24259881-872312346-b2defa6b4904a34b5dfa8d86ebaaae1c7a81931b-1280x720-100x56.png)
